Drug Trial Radar · NCT05948475
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Conditions
- Cholangiocarcinoma
Interventions
Tinengotinib 8 mgDrug
Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
Tinengotinib 10 mgDrug
Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
Physician's ChoiceDrug
For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence, duration, and severity of adverse events (AEs)Time frame: Up to 30 days from study discontinuation
- Part B: PFS by BICRTime frame: From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months
Locations
87 sites in 13 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Santa Monica, California
Stanford Cancer Center
Stanford, California
The University of Kansas Cancer Center
Westwood, Los Angeles, California
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
The University of Chicago Hospitals
Chicago, Illinois
UMass Memorial Medical Center
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford
Detroit, Michigan
University of Minnesota- Masonic Cancer Center, M Health Fairview
Minneapolis, Minnesota
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Messino Cancer Centers
Asheville, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Tennessee Oncology- Nashville
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Texas Oncology-Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Ordensklinikum Linz GmbH
Linz, Austria
Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Institut Sainte Catherine - Institut du Cancer Avignon Provence
Avignon, France
Centre Hospitalier Régional Universitaire de Besançon
Besançon, France
Hopital Beaujon
Clichy, France
Hopital Franco-Britannique - Fondation Cognacq-Jay
Levallois-Perret, France
Clinique de la Sauvegarde
Lyon, France
Centre Hospitalier Universitaire de Montpellier
Montpellier, France
Hopital Saint Antoine
Paris, France
Institut de Cancerologie Gustave Roussy
Villejuif, France
Krebszentrum Reutlingen
Baden, Germany
Krankenhaus Nordwest gGmbH
Frankfurt, Germany
Asklepios Klinik Altona
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitaetsklinikum Heidelberg (UKHD) - Nationales Centrum fuer Tumorerkrankungen Heidelberg (NCT)
Heidelberg, Germany
Ludwig-Maximilians-Universität München Kum
München, Germany
Clinica Oncologica, Ospedali Riuniti Umberto 1
Ancona, Italy
Candiolo Cancer Institute - FPO IRCCS
Candiolo, Italy
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.